Market Overview

Shares of Idenix Pharma Down 7+% After FDA Says Needs Added Time to Review Response Package for IDX184

Related IDIX
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline
Stock Market News for July 01, 2014 - Market News
Stocks Poised to Slip from Record Highs (Fox Business)

Idenix (NASDAQ: IDIX) comments were from the JPMorgan Healthcare Conference last night. Idenix said an FDA response should be sometime during Q1.

Posted-In: News FDA Movers

 

Most Popular

Related Articles (IDIX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters